NCT01505504已完成不适用
Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- body weight
研究概览
简要总结
Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.
The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AD or mixed dementia
- •documented weight loss
- •mirtazapine 30 mg explicitly prescribed against weight loss
排除标准
- •no treatment compliance
- •other causes of weight loss
- •other interventions against weight loss
结局指标
主要结局
body weight
时间窗: 6 months
次要结局
未报告次要终点
研究者
Kurt Segers
Principal Investigator
Brugmann University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Brain Outcomes With Lifestyle Change in Down SyndromeDown SyndromeAlzheimer DiseaseObesityNCT05985486University of Kansas Medical Center81
Unknown
2 期
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage CancerAnorexia Nervosa with Significantly Low Body WeightNCT05170919Englewood Hospital and Medical Center170
已完成
不适用
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With OlanzapineMetabolic SyndromeObesityBipolar DisorderSchizophreniaSchizoaffective DisorderNCT00512070Seattle Institute for Biomedical and Clinical Research40
已完成
4 期
Weight Gain Management in Patients With SchizophreniaSchizophreniaNCT00486005Eli Lilly and Company74
招募中
不适用
Influencing factors on weight gain under mirtazapine? A restrospective analyses of routine datapsychiatric disordersDRKS00031066VR-Klinik Düsseldorf2,000